Sekisui Medical by Numbers
"Accelerate realization of becoming a world leading medical company through strategic investment" is the basic policy of the Midterm Plan. Along with the establishment of global manufacturing, marketing, R&D and pharmaceutical quality assurance systems, and the promotion of consolidated management of our businesses, we are aiming for net sales of 100 billion yen in FY2022.
No. of reagents we make in Japan
The products we deal in include various kinds of clinical reagents, with a particular focus on the fields of blood coagulation, lifestyle related diseases, and infectious diseases. We also offer various kinds of analytical equipment, including plastic vacuum blood collection tubes and fully-automated blood coagulation analyzers that are an integral part of clinical testing.
We are expanding our lineup in each key area, and offer a comprehensive total system of diagnostic reagents and specialized analyzers.
Overseas sales ratio
We have expanded globally, with offices in North America, Europe and China, and the overseas sales ratio exceeds 50% on a consolidated basis.
2022 API sales ratio
The main business is to supply Active Pharmaceutical Ingredients(API)to customers including intermediates and amino acids. We are expanding the business by strengthening small to medium molecule API supply chain.
Japan's first non-governmental
radioisotope laboratory established
We support drug development research, and non-clinical pharmacokinetic trials in particular, in a way that anticipates contemporary needs. In recent years, we carried out Japan's first clinical pharmacokinetic trial utilizing radioisotopes. We provide support to help with the acquisition of Proof of Concept that verifies a drug's effectiveness and safety for humans at an early stage.
Productivity Management 500
We have been accredited by the FY2021 Certified Health & Productivity Management Organization Recognition Program run by the Ministry of Economy, Trade and Industry and Nippon Kenko Kaigi for fourth consecutive years.
SEKISUI CHEMICAL Group's implement health management based upon the approach that "our employees are valuable assets entrusted to us by the wider community". Going forward, we will continue to help our employees to autonomously manage their own health, and we will contribute to society via our business.